Trial Profile

Evaluation of Tolerability and Immunogenicity of GARDASIL in Healthy Females, Between 16 and 26 Years of Age, in India

Status: Withdrawn prior to enrolment

Phase of Trial: Phase III

Latest Information Update: 06 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
Indications Cervical cancer; Human papillomavirus infections
Focus Pharmacodynamics; Registrational
Sponsors Merck Sharp & Dohme Corp.

Most Recent Events

03 Mar 2025 Status changed from suspended to withdrawn prior to enrolment following the direction of the local (India) health authority, data specified in the protocol were not collected and study was cancelled.
13 Jan 2011 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
30 Sep 2010 Planned end date changed from 1 Apr 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com